PARIPEX INDIAN JOURNAL OF RESEARCH
May 15, 2023
Chirag Ambaliya, Dimple Gupta, Ashok Vala et al.
The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and MDMA, in the treatment of various mental health conditions, such as depression, anxiety, PTSD, and substance use disorders. This review's main goal is to highlight recent human studies on the use of particular psychedelic drugs, like psilocybin, LSD,...
March 1, 2023
David Nutt, David Castle
4 citations
Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs; however, the last decade has seen a major renewal of interest in...
Behavioural Brain Research
July 14, 2022
Marina Goulart Da Silva, Guilherme Cabreira Daros, Fabiana Pereira Santos et al.
22 citations
The objective of this study was to evaluate the behavioral response of ayahuasca in rats submitted to neuroinflammation through the intraperitoneal application of lipopolysaccharide (0.63 mg/kg/mL). Eighty animals, male, about 90 days old, were divided into control and LPS groups and later into prevention and treatment subgroups. The prevention subgroup was administered ayahuasca or saline...
European Psychiatry
June 1, 2022
L. Silva, L. Bravo
Introduction Ayahuasca is an hallucinogenic tea prepared from the Amazonian vine Banisteriopsis caapi and the leaves of the plant Psychotria Viridis. Banisteriopsis caapi contains monoamine oxidase inhibitors (MAO) that render the N, N-dimethyltryptamine (DMT) of Psychotria Viridis active. This brew is being used as a sacrament in syncretic religions in urban areas of Brazil and worldwide with...
Substance Use & Misuse
April 25, 2022
Dimitri Daldegan-Bueno, Dóra Révész, Paulo Rogério Morais et al.
15 citations
Background: Preliminary evidence suggests that long-term ayahuasca use is associated with better psychosocial outcomes and less drug use; however, available data on the association between ayahuasca intake frequency and psychosocial outcomes is limited. Objectives: We sought to characterize and investigate the association of regular ayahuasca use, as compared to non-regular use, on licit...
Behavioural Brain Research
April 1, 2022
Dimitri Daldegan-Bueno, Vanessa Manchim Favaro, Paulo Rogério Morais et al.
10 citations
Considering the long-lasting effects of ayahuasca on the brain and emotional processing, the objective of this study was to evaluate the behavioural and neurobiological effects of repeated ayahuasca administration in an animal model of exploratory behaviour related to novel-environment anxiety. Male Wistar rats received water, 120, 240, 480 or 3600 mg/kg of resuspended freeze-dried ayahuasca by...
Journal of Psychopharmacology
March 1, 2022
Max Wolff, Lea J. Mertens, Marie Walter et al.
57 citations
Background: Many benefits and some harms associated with psychedelic use could be attributable to these drugs’ acceptance/avoidance-promoting effects and corresponding changes in psychological flexibility. Underlying psychological mechanisms are insufficiently understood. Aim: The purpose of this study was the validation of a psychological model of acceptance/avoidance-promoting psychedelic...
Journal of the Royal Anthropological Institute
February 24, 2022
Alex K. Gearin
12 citations
Abstract Analysing healing practices at an ayahuasca tourism centre in Peru, this article illustrates how Shipibo practices of curing and sorcery have adapted to the demands of international clients searching for primitivist healing experiences. At the core of this adaption is the thorny issue of occult power and its relation to capital accumulation. Sorcery here does not serve clients but is...
Human Psychopharmacology Clinical and Experimental
February 2, 2022
Rafael G. Dos Santos, Juliana Mendes Rocha, Giordano Novak Rossi et al.
20 citations
Abstract Objective To assess endocannabinoid (anandamide, AEA; 2‐arachidonoylglycerol, 2‐AG) plasma levels in healthy volunteers and in volunteers with social anxiety disorder (SAD) after a single oral dose of ayahuasca or placebo. Methods Post hoc analysis of endocannabinoid plasma levels (baseline, 90 and 240 min after drug intake) from two parallel‐group, randomized, placebo‐controlled...
Frontiers in Psychiatry
2022
Charles L. Raison, Rakesh Jain, Andrew Penn et al.
75 citations
Survey-based studies suggest naturalistic psychedelic use provides mental health benefits similar to those observed in clinical trials. The current study sought to confirm these findings in a large group of psychedelic users and to conduct a novel examination of associations between amount of psychedelic use and behavioral outcomes, as well as frequency of harms ascribed to psychedelic use. A...